Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP7968)
Name
Deguelin
Synonyms
(-)-Deguelin; (-)-cis-deguelin; DEGUELIN(-); UNII-K5Z93K66IE; CHEBI:4357; K5Z93K66IE; MFCD01740600; C23H22O6; (7as,13as)-13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-3h-bis[1]benzopyrano[3,4-b:6',5'-e]pyran-7(7ah)-one; (7aS,13aS)-9,10-Dimethoxy-3,3-dimethyl-13,13a-dihydro-3H-pyrano[2,3-c:6,5-f']dichromen-7(7aH)-one; (7aS,13aS)-9,10-dimethoxy-3,3-dimethyl-13,13a-dihydro-3H-pyrano[2,3-c:6,5-f']dichromen-7(7aH)-one.; SR-01000597503; CCRIS 8104; Deguelin/; (-)-Deguelin, Mundulea sericea; Spectrum_001044; Tocris-1770; Spectrum2_000298; Spectrum3_001122; Spectrum4_001965; Spectrum5_001852; SCHEMBL73183; BSPBio_002583; KBioGR_002434; KBioSS_001524; SPECTRUM201138; MLS006010295; SPBio_000236; CHEMBL393417; KBio2_001524; KBio2_004092; KBio2_006660; KBio3_002083; DTXSID10200231; HMS1923A05; HMS3268E12; 3H-Bis(1)benzopyrano(3,4-b:6',5'-e)pyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS-cis)-; EX-A4158; ZINC3978987; 1702AH; ABP000411; BDBM50505204; CCG-39856; LMPK12060019; s8132; AKOS024456769; ACN-053693; BCP9000596; CS-1802; SDCCGMLS-0066380.P001; NCGC00025288-01; NCGC00025288-02; NCGC00025288-03; (-)-Deguelin, >98% (HPLC), powder; AS-56004; HY-13425; SMR004701363; C10417; Q5251862; SR-01000597503-1; SR-01000597503-3; SR-01000597503-4; BRD-K61401890-001-02-0; BRD-K61401890-001-03-8; BRD-K61401890-001-04-6; (1S,14S)-17,18-dimethoxy-7,7-dimethyl-2,8,21-trioxapentacyclo[12.8.0.03,12.04,9.015,20]docosa-3(12),4(9),5,10,15,17,19-heptaen-13-one; (7aS,13aS)-9,10-Dimethoxy-3,3-dimethyl-13,13a-dihydro-3H,7aH-pyrano[2,3-c;6,5-f']dichromen-7-one; 13,13aS-Dihydro-9,10-dimethoxy-3,3-dimethyl-3H-[1]benzopyrano[3,4-b]pyrano[2,3-h][1]benzopyran-7(7aS)-one; 3H-[1]Benzopyrano[3,4-b]pyrano[2,3-h][1]benzopyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS,13aS)-; 3H-Bis(1)benzopyrano(3,4-b:6',5'-e)pyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS,13aS)-
    Click to Show/Hide
Species Origin Derris trifoliata ...     Click to Show/Hide
Derris trifoliata
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Fabales
Family: Fabaceae
Genus: Derris
Species: Derris trifoliata
Indigofera tinctoria
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Fabales
Family: Fabaceae
Genus: Indigofera
Species: Indigofera tinctoria
Disease Lung cancer [ICD-11: 2C25] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C23H22O6
PubChem CID
107935
Canonical SMILES
CC1(C=CC2=C(O1)C=CC3=C2OC4COC5=CC(=C(C=C5C4C3=O)OC)OC)C
InChI
1S/C23H22O6/c1-23(2)8-7-12-15(29-23)6-5-13-21(24)20-14-9-17(25-3)18(26-4)10-16(14)27-11-19(20)28-22(12)13/h5-10,19-20H,11H2,1-4H3/t19-,20+/m1/s1
InChIKey
ORDAZKGHSNRHTD-UXHICEINSA-N
CAS Number
CAS 522-17-8
Herb ID
HBIN022961
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Cisplatin      Bladder cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Down-regulation Expression BRCA1  Molecule Info 
Pathway MAP
                    In-vitro Model MGC-803 CVCL_5334 Gastric mucinous adenocarcinoma Homo sapiens
                    Experimental
                    Result(s)
The combined treatment of deguelin and cisplatin exhibited a marked inhibition of MGC-803 cell proliferation when compared with that of the single therapies in vitro.
          AG1478      Diabetic retinopathy     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Down-regulation Expression AKT1  Molecule Info 
Pathway MAP
Up-regulation Cleavage PARP1  Molecule Info 
Pathway MAP
                    In-vitro Model HSC-4 CVCL_1289 Tongue squamous cell carcinoma Homo sapiens
Ca9-22 CVCL_1102 Gingival squamous cell carcinoma Homo sapiens
                    Experimental
                    Result(s)
Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
          Doxorubicin      Solid tumour/cancer     Click to Show/Hide the Molecular Data of This Drug
                 Augmenting Drug Sensitivity     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [4]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Up-regulation Cleavage CASP3  Molecule Info 
Pathway MAP
Up-regulation Expression MAP1LC3A  Molecule Info 
Pathway MAP
Up-regulation Expression SQSTM1  Molecule Info 
Pathway MAP
                    In-vitro Model MIA PaCa-2 CVCL_0428 Pancreatic ductal adenocarcinoma Homo sapiens
PANC-1 CVCL_0480 Pancreatic ductal adenocarcinoma Homo sapiens
HPDE CVCL_4376 Healthy Homo sapiens
                    Experimental
                    Result(s)
Inhibition of autophagy by deguelin sensitizes pancreatic cancer cells to doxorubicin.
Target and Pathway
Target(s) Aurora kinase B (AURKB)  Molecule Info  [5]
Aurora kinase C (AURKC)  Molecule Info  [5]
Insulin-like growth factor I receptor (IGF1R)  Molecule Info  [6]
Phosphatase and tensin homolog (PTEN)  Molecule Info  [7]
Transcription factor p65 (RELA)  Molecule Info  [8]
KEGG Pathway Ras signaling pathway Click to Show/Hide
2 Rap1 signaling pathway
3 HIF-1 signaling pathway
4 FoxO signaling pathway
5 Oocyte meiosis
6 Endocytosis
7 PI3K-Akt signaling pathway
8 AMPK signaling pathway
9 Focal adhesion
10 Adherens junction
11 Signaling pathways regulating pluripotency of stem cells
12 Long-term depression
13 Ovarian steroidogenesis
14 Progesterone-mediated oocyte maturation
15 Pathways in cancer
16 Transcriptional misregulation in cancer
17 Proteoglycans in cancer
18 Glioma
19 Prostate cancer
20 Melanoma
Panther Pathway Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade Click to Show/Hide
2 Insulin/IGF pathway-protein kinase B signaling cascade
Pathway Interaction Database Plasma membrane estrogen receptor signaling Click to Show/Hide
2 SHP2 signaling
3 IGF1 pathway
4 Posttranslational regulation of adherens junction stability and dissassembly
5 Integrins in angiogenesis
6 Stabilization and expansion of the E-cadherin adherens junction
7 Aurora B signaling
8 Signaling by Aurora kinases
9 Aurora C signaling
10 FOXM1 transcription factor network
11 Aurora A signaling
Reactome IRS-related events triggered by IGF1R Click to Show/Hide
2 SHC-related events triggered by IGF1R
3 APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
4 Separation of Sister Chromatids
5 Resolution of Sister Chromatid Cohesion
6 RHO GTPases Activate Formins
7 Mitotic Prometaphase
WikiPathways Senescence and Autophagy in Cancer Click to Show/Hide
2 Insulin Signaling
3 Endochondral Ossification
4 Focal Adhesion
5 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
6 Apoptosis
7 Signaling Pathways in Glioblastoma
8 TSH signaling pathway
9 MicroRNAs in cardiomyocyte hypertrophy
10 Mitotic Metaphase and Anaphase
11 Mitotic Prometaphase
12 Regulation of Microtubule Cytoskeleton
13 miR-targeted genes in lymphocytes - TarBase
14 miR-targeted genes in epithelium - TarBase
15 APC/C-mediated degradation of cell cycle proteins
16 EGF/EGFR Signaling Pathway
17 JAK/STAT
18 Gastric Cancer Network 1
19 Integrated Breast Cancer Pathway
References
Reference 1 Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3Beta/FBW7-mediated Mcl-1 destabilization. Cell Death Dis. 2020 Feb 21;11(2):143.
Reference 2 Synergistic antitumor effects of combined deguelin and cisplatin treatment in gastric cancer cells. Oncol Lett. 2014 Oct;8(4):1603-1607.
Reference 3 Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma. Int J Mol Sci. 2017 Jan 26;18(2):262.
Reference 4 Inhibition of Autophagy by Deguelin Sensitizes Pancreatic Cancer Cells to Doxorubicin. Int J Mol Sci. 2017 Feb 10;18(2):370.
Reference 5 Deguelin, an Aurora B Kinase Inhibitor, Exhibits Potent Anti-Tumor Effect in Human Esophageal Squamous Cell Carcinoma. EBioMedicine. 2017 Dec;26:100-111.
Reference 6 A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer. Cancer Lett. 2013 May 10;332(1):102-9.
Reference 7 Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells. Cell Rep. 2018 Apr 3;23(1):58-67.
Reference 8 Deguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial-to-mesenchymal transition in an orthotopic model. Oncogene. 2013 Aug 22;32(34):3980-91.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China